The Difference in Clinical Behavior of Gene Fusions Involving RET/PTC Fusions and THADA/IGF2BP3 Fusions in Thyroid Nodules.
Autor: | Tali G; Faculty of Medicine, McGill University, Montreal, QC H3A 0G4, Canada., Payne AE; Health Science Program, Marianopolis College, Westmount, QC H3Y 1X9, Canada., Hudson TJ; Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, QC H3A 0G4, Canada., da Silva SD; Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, QC H3A 0G4, Canada., Pusztaszeri M; Department of Pathology, Jewish General Hospital, Montreal, QC H3T 1E2, Canada., Tamilia M; Division of Endocrinology, Jewish General Hospital, Montreal, QC H3T 1E2, Canada., Forest VI; Department of Otolaryngology-Head and Neck Surgery, Jewish General Hospital, Montreal, QC H3T 1E2, Canada. |
---|---|
Jazyk: | angličtina |
Zdroj: | Cancers [Cancers (Basel)] 2023 Jun 28; Vol. 15 (13). Date of Electronic Publication: 2023 Jun 28. |
DOI: | 10.3390/cancers15133394 |
Abstrakt: | Background: Molecular testing has been used as an adjunct to morphological evaluation in the workup of thyroid nodules. This study investigated the impact of two gene fusions, RET/PTC and THADA/IGF2BP3 , that have been described as oncogenic events in thyroid neoplasms. Methods: We performed a retrospective, single-centered study at a McGill University teaching hospital in Montreal, Canada, from January 2016 to August 2021. We included patients who underwent surgery for thyroid nodules that pre-operatively underwent molecular testing showing either RET/PTC or THADA/IGF2BP3 gene fusion. Results: This study included 697 consecutive operated thyroid nodules assessed using molecular testing, of which five had the RET/PTC fusion and seven had the THADA/IGF2BP3 fusion. Of the five nodules in the RET/PTC group, 100% were malignant and presented as Bethesda V/VI. Eighty percent (4/5) were found to have lymph node metastasis. Twenty percent (1/5) had extrathyroidal extensions. Sixty percent (3/5) were a diffuse sclerosing variant of papillary thyroid carcinoma, and the rest were the classical variant. Of the seven THADA/IGF2BP3 nodules, all presented as Bethesda III/IV and 71.4% (5/7) were malignant based on the final pathology analysis, and 28.6% (2/7) were NIFTP. All the THADA/IGF2BP3 fusion malignancies were a follicular variant of papillary thyroid carcinoma. None had lymph node metastasis or displayed extrathyroidal extensions. Conclusions: RET/PTC nodules presented as Bethesda V/VI and potentially had more aggressive features, whereas THADA/IGF2BP3 nodules presented as Bethesda III/IV and had more indolent behavior. This understanding may allow clinicians to develop more targeted treatment plans, such as the extent of surgery and adjuvant radioactive iodine treatment. |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |